Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.61
-0.0700-1.50%
Volume:254.15K
Turnover:1.18M
Market Cap:144.25M
PE:-1.12
High:4.69
Open:4.65
Low:4.55
Close:4.68
52wk High:50.40
52wk Low:4.54
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.69
T/O Rate:1.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.66
PE(LYR):-1.62

Loading ...

Lenz Therapeutics Q2 Income from Operations USD -34.172 Million

THOMSON REUTERS
·
Aug 12

Press Release: LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Dow Jones
·
Aug 12

Press Release: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 12

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

GlobeNewswire
·
Aug 12

Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate

Benzinga Earnings
·
Aug 12

Intensity Therapeutics price target lowered to $15 from $30 at Alliance Global

TIPRANKS
·
Aug 12

Analyst Reiterates Buy on Context Therapeutics, Maintains $4 Price Target Amid Promising CTIM‑76 Data and Compelling Valuation

TIPRANKS
·
Aug 12

Aquestive Therapeutics options imply 6.1% move in share price post-earnings

TIPRANKS
·
Aug 12

Gil Blum Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target on Margin Gains and Strong Aucatzyl Trajectory

TIPRANKS
·
Aug 12

Silence Therapeutics is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 12

Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating

MT Newswires Live
·
Aug 11

Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

MT Newswires Live
·
Aug 11

Jefferies Reaffirms Their Buy Rating on Damora Therapeutics (DMRA)

TIPRANKS
·
Aug 11

Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy

TIPRANKS
·
Aug 11

BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20

MT Newswires Live
·
Aug 11

Kalaris Therapeutics Q2 EPS $(0.48) Beats $(0.49) Estimate

Benzinga Earnings
·
Aug 11

Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley

TIPRANKS
·
Aug 11

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

GlobeNewswire
·
Aug 11

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

GlobeNewswire
·
Aug 11

Intensity Therapeutics Q2 EPS $(1.11), Inline

Benzinga Earnings
·
Aug 11